TSN 2898

Drug Profile

TSN 2898

Alternative Names: TSN-2898

Latest Information Update: 03 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Thesan Pharmaceuticals
  • Class Antiacnes; Small molecules
  • Mechanism of Action Stearoyl CoA desaturase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Acne vulgaris

Most Recent Events

  • 03 May 2017 Thesan Pharmaceuticals withdraws a phase II trial in Acne vulgaris in USA due to unavailability of the drug (NCT02796066)
  • 27 Jun 2016 Clinical trials in Acne vulgaris in USA (Topical) prior to June 2016
  • 26 May 2016 Thesan Pharmaceuticals plans a phase II trial for Acne vulgaris in USA (NCT02796066)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top